Chen S

The Affiliated Yongchuan Hospital of Chongqing Medical University

2
EM Publications
1
h-index
(6 citations, 4 total works)

Research Topics

Pain Mechanisms and Treatments (2) Intraocular Surgery and Lenses (2) Musculoskeletal pain and rehabilitation (1) Glaucoma and retinal disorders (1) Corneal surgery and disorders (1)

Erythromelalgia Publications

Case report: Spinal cord stimulation in the treatment of pediatric erythromelalgia.

Zuo L, Su A, Shi Y, Li N, Chen S , et al.
Frontiers in neurology

In children, erythromelalgia is a rare chronic pain syndrome characterized by erythema, severe burning pain, and itching of affected feet. Unfortunately, there is no definitive therapy available currently. Here, we report a case of primary erythromelalgia and the treatment response in a 10-year-old boy, whose genetic findings for mutations in the SCN9A gene were positive and skin biopsy results were diagnosed as small fiber neuropathy, while he has suffered from excruciating burning pain, itching, erythema, and recurrent infections over the past 3 years. He did not respond well to conventional treatment, and the only way to receive minimal relief was to immerse his feet in ice water. After a successful trial of spinal cord stimulation (SCS), the implantable pulse generator (IPG) was successfully implanted without complications, and it proved partial response to therapy. There is no specific, efficient treatment for pediatric erythromelalgia currently, but this case demonstrates neuromodulation serves as part of the multimodal regimen to treat pediatric erythromelalgia.

Effectiveness of botulinum toxin A in treatment of refractory erythromelalgia.

Lin KH, Wang SJ, Fuh JL, Chen SP
Journal of the Chinese Medical Association : JCMA

Erythromelalgia is characterized by intense burning pain, erythema, and heat in affected areas after precipitating factors such as warm temperature or stress. It is refractory to treatment in some situations. We describe a woman with adenosquamous cell carcinoma of the lung and medically refractory erythromelalgia. The symptoms of erythromelalgia presented as refractory to any medical treatment. Due to the unresponsive nature of her condition, botulinum toxin type A (onabotulinumtoxin A) was injected over both of her cheeks, periodically for six cycles. Her symptoms responded dramatically to subcutaneous and intradermal injection of botulinum toxin type A. Repetitive injection demonstrated consistent and reproducible responses, and the efficacy was maintained for approximately 1 month. No adverse effects or complications were noted. Botulinum toxin type A might be safe and effective as an alternative treatment for refractory erythromelalgia, but further large-scale studies are required.